2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Jae Park, MD, discusses considerations for CAR T-cell therapy in relapsed/refractory acute lymphoblastic leukemia.
Jae Park, MD, a hematologist oncologist at Memorial Sloan Kettering Cancer Center, discusses considerations for CAR T-cell therapy in relapsed/refractory acute lymphoblastic leukemia (ALL).
Several factors should be taken into account when considering CAR T-cell therapy for patients with ALL, says Park.
Patients should be consulted early on regarding their eligibility for CAR T-cell therapy, Park explains. Then, optimizing bridging therapy is necessary to ensure patients have the best chance of deriving benefit from CAR T-cell therapy.
Patients are encouraged to reach out regarding any questions they may have as a lot of preparation is involved prior to CAR T-cell administration, Park explains.
In addition, clinical trials can be recommended to eligible patients as ALL remains a rare disease, Park concludes.